Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning Junya Kanda, David.

Slides:

Advertisements

Similar presentations

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,

Advertisements

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide Asha Johny, Kevin W.

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity Sarah J. Stephens, MD, Samantha Thomas, MB,

Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Total Colony-Forming Units Are a Strong, Independent Predictor of Neutrophil and Platelet Engraftment after Unrelated Umbilical Cord Blood Transplantation:

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide,

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization Sarah Anand, Samantha Thomas, Terry Hyslop,

Sabina Kersting, Leo F. Verdonck

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics

Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced.

“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Biology of Blood and Marrow Transplantation

Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus- I–negative Donors for Adult T-Cell Leukemia/Lymphoma: Retrospective.

A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses Seitaro Terakura, Eiichi.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Similar Outcomes of Cryopreserved Allogeneic Peripheral Stem Cell Transplants (PBSCT) Compared to Fresh Allografts Dong Hwan Kim, Nazir Jamal, Ronnie.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Post-Thaw Viable CD45+ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders Mi Kwon,

IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation Thomas.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Richard Mitchell, John E. Wagner, Claudio G

Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies Federico Moscardó, Jaime Sanz, Francisco.

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic.

4-Hydroperoxycyclophosphamide–purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia David A. Rizzieri,

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation

Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment Duncan Purtill,

Transplantation of Unrelated Donor Umbilical Cord Blood for Nonmalignant Diseases: a Single Institution's Experience with 45 Patients Tang-Her Jaing,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation Filippo Milano, Shelly Heimfeld, Ted Gooley,

Cryopreserved CD34+ Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after.

Optimal Donor Selection: Beyond HLA

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning Junya Kanda, David A. Rizzieri, Cristina Gasparetto, Gwynn D. Long, John P. Chute, Keith M. Sullivan, Ashley Morris, Clayton A. Smith, Donna E. Hogge, Janet Nitta, Kevin Song, Donna Niedzwiecki, Nelson J. Chao, Mitchell E. Horwitz Biology of Blood and Marrow Transplantation Volume 17, Issue 6, Pages 867-874 (June 2011) DOI: 10.1016/j.bbmt.2010.09.009 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of (A) neutrophil and (B) platelet engraftment of 50,000/μL. Biology of Blood and Marrow Transplantation 2011 17, 867-874DOI: (10.1016/j.bbmt.2010.09.009) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Dot plots showing the impact of total nucleated cell dose, CD34+ and CD3+ cell dose, and CFU content on establishment of the predominant unit and nondominant units for each patient. (A) Cryopreserved total nucleated cell dose (n = 20), median predominant unit 2.5 × 107/kg (range: 1.7-3.6 × 107/kg), median nondominant unit, 1.8 × 107/kg (range: 1.2-4.2 × 107/kg). (B) Infused total nucleated cell count (n = 19), median dominant unit 2.1 × 107/kg (range: 1.2-3.6 × 107/kg), median nondominant unit, 1.5 × 107/kg (range: 1.0-3.1 × 107/kg). (C) Infused CD34+ cell dose (n = 20), median dominant unit 0.7 × 105/kg (range: 0.2-1.6 × 105/kg), median nondominant unit 0.5 × 105/kg (range: 0.1-2.5 × 105/kg). (D) CD3+ cell count (n = 17), median dominant unit 3.5 × 106/kg (range: 2.2-7.9 × 106/kg), median nondominant unit 3.4 × 106/kg (range: 1.3-5.1 × 106/kg). (E) Colony-forming unit content (n = 20), median dominant unit 6.5 × 104/kg (range: 0.3-28.7 × 104/kg), median nondominant unit 4.5 × 104/kg (range: 0.0-42.6 × 104/kg). Biology of Blood and Marrow Transplantation 2011 17, 867-874DOI: (10.1016/j.bbmt.2010.09.009) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Cumulative incidence of (A) acute and (B) chronic GVHD. Biology of Blood and Marrow Transplantation 2011 17, 867-874DOI: (10.1016/j.bbmt.2010.09.009) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 (A) Overall and (B) disease-free survival, (C) treatment-related mortality, and (D) relapse rates. Biology of Blood and Marrow Transplantation 2011 17, 867-874DOI: (10.1016/j.bbmt.2010.09.009) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Sequential change of myeloid chimerism for 2 patients (A and B) who had long-lasting dual cord blood chimerism. Biology of Blood and Marrow Transplantation 2011 17, 867-874DOI: (10.1016/j.bbmt.2010.09.009) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions